Payment overview · 2025
General Payments
$434.76
25 reported records · 11 companies
Healthcare provider profile · identity verified
Azhar Chaudhry, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ORLANDO, FL · NPI 1669491726
Verified facts
What the public records show
CMS Open Payments records show Azhar Chaudhry, MD received $434.76 in general payments during 2025 across 25 reported records.
GlaxoSmithKline, LLC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $148.90 | 34.2% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.84 | 12.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.87 | 9.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.63 | 8.9% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $37.15 | 8.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.71 | 5.7% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.25 | 5.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.70 | 4.5% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $17.55 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.25 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.91 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $434.76 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $148.90 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 352 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 34 |
| Gabapentin | Gabapentin | 181 | 42 |
| Losartan Potassium | Losartan Potassium | 172 | 47 |
| Lisinopril | Lisinopril | 155 | 43 |
| Donepezil Hcl | Donepezil Hcl | 132 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 35 |
| Metformin Hcl | Metformin Hcl | 126 | 29 |
| Furosemide | Furosemide | 121 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 17 |
| Trazodone Hcl | Trazodone Hcl | 103 | 24 |
| Memantine Hcl | Memantine Hcl | 100 | 19 |
| Carvedilol | Carvedilol | 95 | 24 |
| Potassium Chloride | Potassium Chloride | 95 | 21 |
| Sertraline Hcl | Sertraline Hcl | 95 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 25 |
| Omeprazole | Omeprazole | 90 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 34 |
| Divalproex Sodium | Divalproex Sodium | 87 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 30 |
| Tramadol Hcl | Tramadol Hcl | 83 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 18 |
| Levetiracetam | Levetiracetam | 77 | 15 |
| Simvastatin | Simvastatin | 76 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 65 | suppressed |
| Clonazepam | Clonazepam | 62 | 12 |
| Jardiance | Empagliflozin | 60 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 12 |
| Allopurinol | Allopurinol | 55 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Montelukast Sodium | Montelukast Sodium | 48 | 12 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | suppressed |
| Glipizide Er | Glipizide | 42 | 11 |
| Mounjaro | Tirzepatide | 42 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | 12 |
| Finasteride | Finasteride | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 20 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 13 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 36 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 16 |
| Alprazolam | Alprazolam | 34 | 13 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Prednisone | Prednisone | 34 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Famotidine | Famotidine | 31 | 14 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 29 | 13 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | suppressed |
| Ozempic | Semaglutide | 28 | 13 |
| Valsartan | Valsartan | 28 | suppressed |
| Meloxicam | Meloxicam | 27 | 17 |
| Ondansetron Odt | Ondansetron | 27 | 23 |
| Belsomra | Suvorexant | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 19 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 16 |
| Atenolol | Atenolol | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Linzess | Linaclotide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 11 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | 12 |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 14 |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $434.76 · 25 records | GlaxoSmithKline, LLC. | BREZTRI, FARXIGA, FREESTYLE LIBRE 3, GLYCATE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Korlym, MOUNJARO, OTEZLA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, TRELEGY ELLIPTA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error